Symbols

BTAI

Bioxcel Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 2

Consensus Rating "Strong Buy"

Revenue Beats Expectation

EPS Beats Expectation

Price Hits New Low

Price Hits 52-week Low

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BTAI

Bioxcel Therapeutics, Inc.

A biopharmaceutical company developing novel therapeutics for neuroscience and immuno-oncology disorders

Industry

Pharmaceutical

Established Date

03/29/2017

Listing Date

03/08/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.bioxceltherapeutics.com

Security Type

Common stock

Office address

555 Long Wharf Drive New Haven CT 06511

Business

Introduction

Bioxcel Therapeutics, Inc., a Delaware corporation, was incorporated on March 29, 2017 and is a wholly-owned subsidiary of BioXcel. The company is a biopharmaceutical company that leverages artificial intelligence platforms to develop transformative drugs in neuroscience. Its commercial product IGALMI has been approved for the treatment of acute agitation associated with schizophrenia and bipolar disorder, and its R&D pipeline includes drug candidates for agitation of Alzheimer's disease and immuno-oncology assets.

Company Financials

EPS

BTAI has released its 2025 Q4 earnings. EPS was reported at -0.58, versus the expected -0.64, beating expectations. The chart below visualizes how BTAI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BTAI has released its 2025 Q4 earnings report, with revenue of 256.00K, reflecting a YoY change of -30.05%, and net profit of -12.54M, showing a YoY change of -15.53%. The Sankey diagram below clearly presents BTAI's revenue sources and cost distribution.